New and potent quinuclidine based antimicrobial agents by Radman Kastelic, Andreja et al.
molecules
Article
New and Potent Quinuclidine-Based
Antimicrobial Agents
Andreja Radman Kastelic 1, Renata Odžak 2, Iskra Pezdirc 3, Karlo Sovic´ 1, Tomica Hrenar 1,
Ana Cˇipak Gašparovic´ 4, Mirjana Skocˇibušic´ 5,* and Ines Primožicˇ 1,*
1 Department of Chemistry, Faculty of Science, University of Zagreb, Horvatovac 102a,
HR-10000 Zagreb, Croatia
2 Department of Chemistry, Faculty of Science, University of Split, R. Boškovic´a 33, HR-21000 Split, Croatia
3 KB “Sestre milosrdnice”, Vinogradska cesta 29, HR-10000 Zagreb, Croatia
4 Institut Ruđer Boškovic´, Bijenicˇka cesta 54, HR-10000 Zagreb, Croatia
5 Department of Biology, Faculty of Science, University of Split, R. Boškovic´a 33, HR-21000 Split, Croatia
* Correspondence: mirjana.skocibusic@pmfst.hr (M.S.); ines.primozic@chem.pmf.hr (I.P.);
Tel.: +385-21-619-292 (M.S.); +385-1-4606-408 (I.P.)
Received: 9 June 2019; Accepted: 18 July 2019; Published: 23 July 2019


Abstract: Developing new antibiotics is currently very important since antibiotic resistance is one of
the biggest problems of global health today. In the search for a new class of potential antimicrobial
agents, ten new compounds were designed and synthesized based on the quinuclidinium heterocyclic
core and the oxime functional group. The antimicrobial activity was assessed against a panel of
representative gram-positive and gram-negative bacteria. All compounds demonstrated potent
activity against the tested microorganisms, with the minimum inhibitory concentration (MIC) values
ranging from 0.25 to 256.00 µg/mL. Among the tested compounds, two quaternary compounds,
para-N-chlorobenzyl and meta-N-bromobenzyl quinuclidinium oximes, displayed the most potent and
broad-spectrum activity against both gram-positive and gram-negative bacterial strains (MIC values
from 0.25 to 4.00 µg/mL), with the lowest value for the important multidrug resistant gram-negative
pathogen Pseudomonas aeruginosa. In the case of Klebsiella pneumoniae, activity of those compounds are
256-fold and 16-fold better than gentamicin, respectively. MTT assays showed that compounds are
nontoxic for human cell lines. Multi-way analysis was used to separately reduce dimensionality of
quantum chemical data and biological activity data to obtain a regression model and the required
parameters for the enhancement of biological activity.
Keywords: antimicrobial potency; quinuclidinium oximes; gram-positive and gram-negative bacteria;
multi-way analysis
1. Introduction
Infectious diseases are the second leading cause of death worldwide and cause significant morbidity,
having a profound effect on global health [1]. The emergence of multidrug-resistant bacteria has become
a serious threat to public health and is considered one of the greatest challenges for contemporary
medicine. The ESKAPE group of bacterial pathogens (Enterococcus faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) is
responsible for a majority of hospital-acquired infections and presents critical threats in nosocomial
pathogenesis, transmission, and resistance [2,3]. Various health organizations have spoken about
the urgent need to develop new antibiotics, especially against drug-resistant gram-negative ESKAPE
bacilli. For instance, the World Health Organization (WHO) has raised its utmost concern about the
post-antibiotic era where common infections and minor injuries may result in significant morbidity
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and mortality [4]. An important potential strategy to help combat the resistance problem involves the
discovery and development of new active agents capable of partly or completely suppressing bacterial
resistance mechanisms.
Heterocyclic compounds are the key motifs in a wide range of natural products such as vitamins,
carbohydrates, and nucleic and amino acids, and medicinal chemistry often engages in stimulating
such natural motifs. Heterocyclic compounds constitute a major portion of the currently approved
drugs by the Food and Drug Administration (FDA), and over 80% of top small molecule drugs by US
retail sales in 2010 contain at least one heterocyclic fragment in their structure [5]. Synthetic heterocycles
have widespread therapeutic uses such as antibacterial, antifungal, antimycobacterial, trypanocidal,
anti-HIV activity, antileishmanial agents, genotoxic, antitubercular, antimalarial, herbicidal, analgesic,
anti-inflammatory, muscle relaxants, anticonvulsant, anticancer and lipid peroxidation inhibitor,
hypnotics, antidepressant, antitumoral, and anthelmintic and insecticidal agents [6–10].
Quinuclidine, a bicyclic heterocyclic compound, is found in many natural products such as
the bark of Cinchona trees and is isolated by alkaloid extraction [11]. It has also been used in the
synthesis of catalysts which are useful in asymmetric reactions such as aldol reactions, Henry and
Aza–Henry reactions, Diels–Alder reactions, etc. [12,13]. Quinuclidine moiety is used to prepare
various therapeutically potent derivatives, such as FDA-approved drugs Azasetron, Benzoclidine,
Palonosetron, Solifenacin, and Quinupramine, which contain Quinuclidine as its main component
(Figure 1) [14].
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against most gram-positive and clinically relevant gram-negative bacterial strains compared to 77 
conventional antimicrobial agents. One of the expected antimicrobial mechanisms of cationic 78 
N
O
OHN
N
Cl
CH3
O
N
N
N
N
O
O
NO
SH3C
N
O
H
N
N
O
O
a) b) c)
d) e) f)
Figure 1. Quinuclidine-3-yl-based drugs: (a) Azasetron; (b) Solifenacin; (c) Quinupramine;
(d) Palonosetron; (e) Cevimeline; and (f) Benzoclidine.
Avibactam, the first non-β-lactam β-lactamase inhibitor, is also a quinuclidine-based drug, which
showed excellent inhibitory activity against most class A and class C and some class D β-lactamases
and is proven to inhibit penicillin-binding proteins. Thus, quinuclidines are recognized as a desirable
structure and a useful template for design of novel compounds with potential pharmacological interest.
In our recent work, we reported synthesis of novel quaternary 3-hydroxy [15,16] and
3-hydroxyimino [17] quinuclidinium bromides with different alkyl chains lengths (3–16 carbon
atoms) and showed that bicyclic quinuclidinium compunds have excellent and promising activity
against most gram-positive and clinically relevant gram-negative bacterial strains compared to
conventional antimicrobial agents. One of the expected antimicrobial mechanisms of cationic biocides
involves the destructive interaction with the outer membrane [18]. In this work, ten different
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quaternary N-alkyl/alkylaryl derivatives of 3-hydroxyiminoquinuclidine were prepared; see Figure 2.
All compounds are new and not previously described in the literature. For all compounds, antimicrobial
activity toward multidrug-resistant gram-negative and gram-positive bacteria was estimated.
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Figure 2. Synthesized compounds: 3-hydroxyiminoquinuclidine (qox) and quaternary derivatives 1–10.
2. Results and Discussion
2.1. Synthesis of Compounds
The initial compound for the oxime synthesis was quinuclidin-3-one prepared from commercially
available quinuclidin-3-one hydrochloride by a previously described procedure with potassium
carbonate as a base in a high yield [19]. 3-Hydroxyiminoquinuclidi e was prepared by the reaction
of quinuclidin-3-one with hydroxylamine hydrochloride and sodi m hydroxide [20] (Figure 3).
NMR analysis showed that prepared oxime has an (E)-configuration which is expected to e
t rmodynamically favored as determined previously [17]. To prepare compoun s 1–10, a Menshutkin
reaction was employed to c nvert tertiary amine to qu ter ary ammonium salt by the reaction of
appropriate alkyl/aryl halide. As rul , the optimal conditions were btained with 1 eq. of alkyl/aryl
bromide in dry tetrahydrofurane at reflux t mp rature und r nitrog n tmosphere. The products
were btained in 60–90% yield, and ll of them were solids that precipitated from the reaction mixture
using diethyl ether. The pKa values for the oxime hydroxyl group and th quinuclidine nitrog n atom
of qox were already d termined experimentally: 10.805 ± 0.030 and 8.072 ± 0.034, resp ctively [17].
As expected, a positive charge on the quinuclidinium nitrogen atom upon quarternization stabilizes
the conjugated base and the acidity of the oxime group of com ound 10 is increased to 1 .05 ± 0.03.
Compounds 1–10 are new compounds nd are not previously described in the literature.
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Figure 3. The synthetic route to target compounds. Reagents and conditions: (a) K2CO3, H2O, Et2O,
25 ◦C, 30 min; (b) NH2OH × HCl, NaOH, MeOH, 25 ◦C, 1 h; and (c) alkyl/aryl bromide, THF, Et2O,
66 ◦C, 5 h.
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2.2. Antimicrobial Activity
In this study, all synthesized novel N-alkyl derivatives of quinuclidinium oximes 1–10 were
preliminary screened against a diverse panel of selected antibiotic susceptible gram-positive
bacteria purchased from the American Type Culture Collection (ATCC), Rockville, MD, USA:
Bacillus cereus ATCC 11778, Enterococcus faecalis ATCC 29212, Staphylococcus aureus ATCC 25923,
and Clostridium perfringens; and antibiotic resistant gram-negative bacteria obtained from Microbiology
Laboratory, Department of Biology, Faculty of Science, University of Split, Croatia (FNSST):
Escherichia coli FNSST 982, Klebsiella pneumoniae FNSST 011, and Pseudomonas aeruginosa FNSST
982 by disc diffusion assay. Cefotaxime and gentamicin, which are well-known relevant antimicrobial
agents [21,22] were included in the assays, serving as positive controls and as a basis for comparison.
The compounds showed to be active against antibiotic susceptible gram-positive bacteria but also
exhibited significant antibacterial effects against gram-negative gentamicin-resistant isolates. As shown
in Table 1, the results of the disc diffusion assay pointed out that the compounds exhibit moderate
to high potency and broad spectrum activity against the bacterial strains tested. The mean zones
of inhibition of the target compounds against all bacterial strains tested were found in the range of
6.2 ± 1.3 to 29.8 ± 1.3 mm. It is noteworthy that, among the synthesized compounds, unsubstituted
nonquaternary 3-hydroxyiminoquinuclidine (QOX) showed very poor activity against all strains tested
(7.6 ± 1.1 to 10.8 ± 1.4 mm). The antimicrobial activity trend did not change significantly for quaternary
compound 1 with butenyl group as a substituent, but the compounds containing benzyl moiety showed
appreciably better antimicrobial effects; see Table 1. As expected, the strongest and most promising
antimicrobial potential against a panel of tested strains was observed with compounds which have a
halogen atom as a substituent (5 and 6 with chlorine atoms at the meta and para positions of the benzyl
substituent and 9 and 10 with bromine atoms). Among all tested derivatives, 10 showed the maximum
inhibition against all tested bacterial strains (21.0 ± 0.8 to 29.8 ± 0.1.3 mm). The highest antibacterial
activity was recorded against Pseudomonas aeruginosa, followed by Klebsiella pneumoniae and Bacillus
cereus.
Table 1. Antimicrobial activity of 3-hydroxyiminoquinuclidine (qox) and its quaternary salts (1–10) by
disc diffusion assay.
Comp. Diameters of the Inhibition Zone (mm)
Gram-Positive Bacteria Gram-Negative Bacteria
Bacillus
cereus
Enterococcus
faecalis
Staphylococcus
aureus
Escherichia
coli
Klebsiella
pneumoniae
Pseudomonas
aeruginosa
qox 8.2 ± 0.9 7.7 ± 1.4 10.4 ± 1.7 8.6 ± 1.9 7.6 ± 1.1 10.8 ± 1.4
1 9.9 ± 1.4 6.2 ± 1.3 9.3 ± 0.8 9.6 ± 1.1 8.4 ± 1.1 12.1 ± 1.8
2 12.1 ± 1.8 14.2 ± 2.1 15.7 ± 1.7 14.8 ± 1.2 16.1 ± 0.9 19.2 ± 1.4
3 10.4 ± 1.5 12.7 ± 1.4 13.5 ± 1.7 15.1 ± 1.2 13.7 ± 1.8 16.3 ± 1.5
4 16.1 ± 0.4 15.4 ± 1.2 18.1 ± 1.1 17.7 ± 0.9 14.7 ± 0.4 18.7 ± 0.9
5 18.2 ± 1.2 19.4 ± 1.8 20.8 ± 1.1 20.8 ± 2.1 19.8 ± 0.4 24.8 ± 1.7
6 16.8 ± 0.8 17.4 ± 1.7 17.2 ± 0.3 19.1 ± 1.5 18.1 ± 1.8 20.1 ± 2.1
7 10.8 ± 1.7 6.4 ± 2.1 9.5 ± 1.3 8.1 ± 1.2 7.5 ± 1.4 11.0 ± 0.8
8 7.8 ± 0.3 9.6 ± 1.2 11.4 ± 0.7 6.6 ± 1.1 8.6 ± 1.1 10.6 ± 1.1
9 23.5 ± 1.3 17.3 ± 2.4 27.2 ± 1.3 22.7 ± 0.8 24.7 ± 1.3 27.6 ± 1.7
10 24.0 ± 1.2 23.0 ± 1.4 21.0 ± 0.8 22.4 ± 0.9 25.1 ± 0.6 29.8 ± 1.3
Gen 18.2 ± 0.7 13.2 ± 0.6 23.9 ± 0.4 11.5 ± 0.9 16.9 ± 0.3 9.4 ± 0.6
Antimicrobial efficacy was also evaluated by the broth microdilution method to determine the
minimum inhibitory concentrations (MICs) of a series of novel derivatives of quinuclidinium oxime
derivatives necessary to inhibit bacterial growth. Cefotaxime and gentamicin were also included in the
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assays as positive controls. The results presented in Table 2 show moderate to excellent antibacterial
activity against tested strains with MIC values from 0.25 to 256.00 µg/mL. Nonquaternary derivative
qox showed very poor activity against all strains tested (MIC = 256 µg/mL except for S. aureus and
P. aeruginosa 128 µg/mL). On the other hand, evaluations pointed out compound 10 as the most
active compound in the series, especially against gram-negative bacteria (MIC values from 0.25 to
1.00 µg/mL). Compound 10 exhibited excellent in vitro activity against a broad spectrum of clinically
important resistant gram-negative pathogens such as Pseudomonas aeruginosa (MIC = 0.25 µg/mL) and
Klebsiella pneumoniae (MIC = 0.50 µg/mL). These MICs are 256-fold and 16-fold better than gentamicin,
respectively. Compound 5 also showed very strong activity against all tested gram-negative bacteria,
with MIC values from 0.25 to 1.00 µg/mL. Compounds 7 and 8 showed very weak antimicrobial
properties among quaternary derivatives. These compounds have a methyl group as a substituent
on an aromatic ring that donates electrons, unlike the electronegative nitro group and halogen atom
present in other substituted compounds. The data indicate that, in general, the quaternary N-benzyl
derivatives of quinuclidine oximes 2–10 are more potent and have broader antimicrobial activity
spectrums compared to their uncharged analog qox and butyl derivative 1. A comparison of meta- and
para-substituted derivatives reveals that the position of the substituent at the benzyl moiety does not
correlate with antimicrobial efficacy.
Table 2. In vitro antibacterial activities for compounds 1–10 expressed as minimum inhibitory
concentrations (MIC; µg/mL) a,b.
Comp. MIC (µg/mL)
Gram-Positive Bacteria Gram-Negative Bacteria
B. cereus E. faecalis S. aureus E. coli K. pneumoniae P. aeruginosa
1 128.00 256.00 128.00 128.00 256.00 128.00
2 64.00 64.00 32.00 16.00 16.00 8.00
3 64.00 32.00 32.00 16.00 64.00 32.00
4 32.00 16.00 16.00 32.00 32.00 16.00
5 4.00 2.00 1.00 1.00 2.00 0.25
6 8.00 4.00 4.00 4.00 8.00 2.00
7 64.00 128.00 64.00 128.00 256.00 32.00
8 128.00 64.00 64.00 256.00 128.00 128.00
9 1.00 8.00 12.50 25.00 50.00 0.50
10 1.00 4.00 2.00 1.00 0.50 0.25
Gentamicin 4.00 4.00 1.00 32.00 8.00 64.00
Cefotaxime 0.25 0.50 0.50 0.50 0.50 16.00
a Minimum inhibitory concentrations were determined by the micro broth dilution method for microdilution plates.
b Gentamicin and cefotaxime were used as the positive controls.
2.3. MTT Assay
The results of MTT assay are shown in Figure 4. Compared to normal physiological cell growth,
the compounds did not cause significant changes in HaCat or HMEC cell growth; see Figure 4a.
In addition, testing a wider concentration range of compounds with confirmed antibacterial activity
showed no changes in cell viability; see Figure 4b.
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2.4. Effects of the Compounds on Cellular Reactive Oxygen Species and Antioxidative Defence
The effects of the compounds with antibacterial activity, 5, 6, 9, and 10, were further tested for the
ability to change intracellular reactive oxygen species (ROS) levels and on the cellular antioxidative
defense system glutathione (GSH) and catalase (Figure 5). The HMEC cell line showed higher basal
levels of ROS when compared to the HaCaT cell line (p < 0.05) (Figure 5a). The compounds had
different effects on ROS level depending on the cell line. In HaCaT cells, 5, 6, 9, and 10 increased ROS
at the lowest concentration applied and the effect diminished with increasing concentration of the
compound. In HMEC cells, the compounds decreased ROS with the exception of 1 µM of 5 (p < 0.05).
These results are in accordance with catalase activity (Figure 5b). In HaCaT cells, catalase activity is
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changed neither by DMSO nor the compounds. In contrast, in HMEC cells, the activity increased with
addition of DMSO and the compounds; therefore, the effects of the compounds themselves cannot be
resolved, as their effect on catalase activity is the same as that of DMSO. Unlike catalase, GSH levels are
not changed by the addition of DMSO, 5, 6, 9, or 10, with the exception of 200 µM of 6 in HMEC cells
(Figure 5c). These results indicate that DMSO could cause a slight shift in the cellular redox balance
but without influencing cell viability. The potential mechanism is to be investigated.
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2.5. Multi-Way Analysis
To additionally improve the relationship between structure and antimicrobial activity, tensor
decomposition methods were utilized on the potential energy surfaces (PES) and biological activity
data. First, a full conformational analysis for all compounds was performed. Conformers were
determined by using the recently developed approach consisting of ab initio molecular dynamics
and probability search in reduced space [23]. The example of conducted conformational analysis is
presented on Figure 6.
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of two-dimensional PES, which was calculated in dependence on two torsional coordinates (Scheme 1).
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Equivalent torsional coordinates were used for all other compounds. After the 2-D PES scan,
a multi-way analysis of energy data was performed for compounds 2–10. Tensor of PES data was
decomposed using the Tucker3 model, and the first principal component described 91% of the total
variance among the data, providing an excellent description of molecular energetics. On the other
hand, biological activity data were decomposed using principal component analysis (PCA) and the first
principal component described 82% of the total variance among the data. Again, this one component
was sufficient to describe all important trends in biological activity data. A polynomial regression
model between the biological activity and potential energy surfaces was established and is presented
on Figure 7.
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surfaces. It can be seen that the two most active compounds 5 and 10 have almost the same value along
the first principal component describing biological activity. In a similar matter, the two least active
derivatives 7 and 8 present extrema points on the activity axis. A regression model between calculated
potential energy surfaces and biological activity enables in silico experiments with compounds having
slightly different variations in the structure. In this way, the structure of compounds can be adjusted
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the validity of the established model, a leave-one-out cross validation procedure was performed.
The mean squared error of prediction in dependence on the polynomial degree is presented in Figure 8.
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3. Materials and Methods
3.1. Synthesis of Compounds
All reagents and solvents were used as purchased from commercial suppliers without further
purification. Thin-layer chromatography (TLC) was performed on Aluminum oxide 60 F254 plates
(Sigma-Aldrich, St. Louis, MO, USA) and visualized under UV light (254 nm) or by iodine fumes.
Melting points were determined on a Melting Point B-540 apparatus (Büchi Labortechnik GmbH, Essen,
Germany) and are uncorrected. Elemental analysis (CHN) was performed on a Perkin Elmer 2400 Series
II CHNS analyzer (PerkinElmer, Inc., Waltham, MA, USA), and the purity of all compounds was ≥99%.
FTIR spectra were recorded as KBr pellets on a Perkin-Elmer Spectrum Two (PerkinElmer, Inc., Waltham,
MA, USA), and the signals were reported in cm−1. NMR spectra were recorded on a Bruker Avance III
HD 400 MHz/54 mm Ascend spectrometer (Bruker Corporation, Billerica, MA, USA) at 22 ◦C in CDCl3
and DMSO with tetramethylsilane as the internal standard. Chemical shifts are given in ppm downfield
from tetramethylsilane as the internal standard, and coupling constants are given (J) in Hz. Splitting
patterns are designated as s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), or m
(multiplet). Anhydrous reactions were carried out in dried glassware under a nitrogen atmosphere.
The compound qox was synthesized from quinuclidin-3-one hydrochloride (≥98.0%, Fluka, Honeywell
Research Chemicals, Charlotte, NC USA) following published procedure [20]. Compound 1 was
prepared in the reaction of qox with butenyl bromide, 2 was prepared with benzyl bromide, and 3–10
were prepared with appropriate meta- and para-substituted benzyl bromides. All halides were obtained
from Sigma–Aldrich Co., St. Louis, MO, USA and used without further purification.
General Procedure for the Synthesis of N-quaternary 3-hydroxyiminoquinuclidinium bromides 1–10
To the solution of 3-hydroxyquinuclidine (1 mmol) in minimal volume of dry tetrahydrofuran
equimolar amount of the appropriate quaternization reagent (butenyl bromide benzyl bromide, para-
and meta-nitrobenzyl bromide, para- and meta-chlorobenzyl bromide, para- and meta-methylbenzyl
bromide, and para- and meta-bromobenzyl bromide each) was added at room temperature. The reaction
mixture was refluxed overnight under nitrogen atmosphere to obtain a solid product which was
washed several times with dry diethyl ether. Digestion gave appropriate quaternary compounds as
white solids.
N-but-3-enyl-3-hydroxyquinuclidinium bromide (1). Yield: 62%; mp: 211.5–212.1 ◦C; IR (KBr) ∼ν/cm−1:
3319–2686, 1643, 1463, 1423, 1085, 838, 700. 1H NMR (400 MHz, DMSO-d6) δ/ppm: 1.89–2.14 (m, 4H,
H8, H5), 2.48–2.56 (m, 2H, H10), 2.79–2.82 (m, 1H, H4), 3.37–3.66 (m, 8H, H6, H7, H9), 4.36 (s, 2H, H2),
5.13–5.26 (m, 2H, H12), 5.72–5.83 (m, 1H, H11), 11.15 (s, 1H, C=N–OH). 13C NMR (101 MHz, DMSO-d6)
δ/ppm: 23.53 (C5, C8), 26.48 (C10), 26.95 (C4), 54.73 (C6, C7), 57.73 (C2), 62.48 (C9), 118.86 (C12), 133.62
(C11), 151.62 (C3). CHN analysis/%: Anal. calcd. for C11H19BrN2O: C 48.01; H 6.96; Br 29.04; N 10.18;
O 5.81. Found: C 48.14; H 6.95; N 10.20.
N-benzyl-3-hydroxyiminoquinuclidinium bromide (2). Yield: 85%; mp: 219.7–222.6 ◦C; IR (KBr)∼
ν/cm−1: 3390–2689, 1673, 1460, 1419, 1063, 944, 770, 713. 1H NMR (400 MHz, DMSO-d6) δ/ppm:
1.88–2.15 (m, 4H, H5, H8), 2.76–2.81 (m, 1H, H4), 3.49–3.66 (m, 4H, H6, H7), 4.32 (m, 2H, H2), 4.66–4.69
(m, 2H, Ar-CH2), 7.54–7.57 (m, 5H, Ar), 11.14 (s, 1H C=N–OH). 13C NMR (101 MHz, DMSO-d6) δ/ppm:
23.49 (C5, C8), 27.47 (C4), 54.55 (C6, C7), 57.31 (C2), 66.64 (C9), 127.81 (C10), 129.55; 130.79; 133.54;
(C11-C15), 151.41 (C3). CHN analysis/%: Anal. calcd. for C14H19BrN2O: C 54.03, H 6.15, Br 25.67, N
9.00, O 5.14. Found: C 53.88, H 6.16, N 9.02.
N-(para-nitrobenzyl)-3-hydroxyiminoquinuclidinium bromide (3). Yield: 91%; mp: 232.5–233.2 ◦C;
IR (KBr)
∼
ν/cm−1: 3214–2846, 1608, 1524, 1353, 958, 856, 706. 1H NMR (400 MHz, DMSO-d6) δ/ppm:
1.88–2.15 (m, 4H, H5, H8), 2.76–2.81 (m, 1H H4), 3.49–3.66 (m, 4H, H6, H7), 4.37 (m, 2H, H2), 4.83 (s,
2H, Ar-CH2), 7.84–7.89 (m, 2H, H11, H15), 8.36–8.41 (m, 2H, H12, H14), 11.16 (s, 1H C=N–OH). 13C
NMR (101 MHz, DMSO-d6) δ/ppm: 23.52 (C5, C8), 27.33 (C4), 54.87 (C6, C7), 57.51 (C2), 65.19 (C9),
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134.89 (C10), 124.40 (C11, C15), 135.14 (C12,C14), 149.12 (C13), 151.21 (C3). CHN analysis/%: Anal.
calcd. for C14H18BrN3O3: C 47.20, H 5.09, Br 22.43, N 11.80, O 13.47. Found: C 47.10, H 5.08, N 11.81.
N-(meta-nitrobenzyl)-3-hydroxyiminoquinuclidinium bromide (4). Yield: 81%; mp: 261–262.6 ◦C; IR
(KBr)
∼
ν/cm−1: 3377–2846, 1670, 1618, 1531, 1353, 945, 707. 1H NMR (400 MHz, DMSO-d6) δ/ppm:
1.88–2.15 (m, 4H, H5, H8), 2.76–2.81 (m, 1H H4), 3.49–3.66 (m, 4H, H6, H7), 4.32 (m, 2H, H2), 4.66–4.69
(m, 2H, Ar–CH2), 7.80–7.89 (m, 1H, H14), 8.00–8.06 (m, 1H, H15), 8.38–8.42 (m, 1H, H13), 8.45–8.47
(m, 1H, H11), 11.16 (s, 1H C=N–OH). 13C NMR (101 MHz, DMSO-d6) δ/ppm: 23.52 (C5, C8), 27.41
(C4), 54.76 (C6, C7), 57.45 (C2), 65.21 (C9), 129.78 (C10), 125.60, 125.25, 131.16, 140.10 (C11–C15), 148.49
(C12), 151.23 (C3). CHN analysis/%: Anal. calcd. for C14H18BrN3O3: C 47.20, H 5.09, Br 22.43, N 11.80,
O 13.47. Found: C 47.32, H 5.10, N 11.81.
N-(para-chlorobenzyl)-3-hydroxyiminoquinuclidinium bromide (5). Yield: 92%; mp: 239.7–240.3 ◦C; IR
(KBr)
∼
ν/cm−1: 3184–2781, 1652, 1598, 1493, 1437, 1384, 951, 883, 626. 1H NMR (400 MHz, DMSO-d6)
δ/ppm: 1.88–2.15 (m, 4H, H5, H8), 2.76–2.81 (m, 1H H4), 3.49–3.63 (m, 4H, H6, H7), 4.32 (m, 2H, H2),
4.68 (s, 2H, Ar–CH2), 7.56–7.65 (m, 4H, H11, H12, H14, H15), 11.14 (s, 1H C=N–OH). 13C NMR (101
MHz, DMSO-d6) δ/ppm: 23.49 (C5, C8), 27.44 (C4), 54.54 (C6, C7), 57.28 (C2), 65.64 (C9), 126.80 (C10),
129.59 (C11, C15), 135.65 (C12,C14), 135.80 (C13), 151.35 (C3). CHN analysis/%: Anal. calcd. for
C14H18BrClN2O: C 48.65, H 5.25, Br 23.12, Cl 10.26, N 8.10, O 4.63. Found: C 48.52, H 5.26, N 8.12.
N-(meta-chlorobenzyl)-3-hydroxyiminoquinuclidinium bromide (6). Yield: 89%; mp: 239.2–241.0 ◦C;
IR (KBr)
∼
ν/cm−1: 3445–2825, 1675, 1574, 1467, 1378, 934, 796, 715. 1H NMR (400 MHz, DMSO-d6)
δ/ppm: 1.88–2.15 (m, 4H, H5, H8), 2.76–2.81 (m, 1H H4), 3.49–3.66 (m, 4H, H6, H7), 4.34 (m, 2H, H2),
4.68 (s, 2H, Ar–CH2), 7.52–7.71 (m, 4H, H11, H13, H14, H15), 11.15 (s, 1H C=N–OH). 13C NMR (101
MHz, DMSO-d6) δ/ppm: 23.50 (C5,C8), 27.39 (C4), 54.74 (C6, C7), 57.44 (C2), 65.69 (C9), 130.11 (C10),
130.81, 131.40, 132.33, 133.13 (C11-C15), 134.01 (C12), 151.32 (C3). CHN analysis/%: Anal. calcd. for
C14H18BrClN2O: C 48.65; H 5.25; Br 23.12; Cl 10.26; N 8.10; O 4.63. Found: C 48.53, H 5.26, N 8.08.
N-(para-methylbenzyl)-3-hydroxyiminoquinuclidinium bromide (7). Yield: 94%; mp: 233.4–233.9 ◦C;
IR (KBr)
∼
ν/cm−1: 2992–3228, 1674, 1611, 1513, 1460, 1376, 1064, 1029, 956, 829, 689. 1H NMR (400 MHz,
DMSO-d6) δ/ppm: 1.87–2.15 (m, 4H, H5, H8), 2.36 (s, 3H, CH3), 2.75–2.80 (m, 1H H4), 3.46–3.62 (m, 4H,
H6, H7), 4.30 (m, 2H, H2), 4.62 (s, 2H, Ar–CH2), 7.31–7.39 (m, 2H, H11, H15), 7.40–7.46 (m, 2H, H12,
H14), 11.13 (s, 1H C=N–OH), 13C NMR (101 MHz, DMSO-d6) δ/ppm: 21.34 (CH3), 23.48 (C5, C8), 27.50
(C4), 54.41 (C6, C7), 57.22 (C2), 66.49 (C9), 124.79 (C10), 130.09 (C11, C15), 133.41 (C12,C14), 140.50
(C13), 151.44 (C3). CHN analysis/%: Anal. calcd. for C15H21BrN2O: C 55.39; H 6.51, Br 24.57, N 8.61, O
4.92. Found: C 55.49, H 6.52, N 8.60.
N-(meta-methylbenzyl)-3-hydroxyiminoquinuclidinium bromide (8). Yield: 91%; mp: 218.6–219.4 ◦C;
IR (KBr)
∼
ν/cm−1: 3511, 3433–2758, 1671, 1659, 1466, 1418, 1381, 940, 887, 797, 711. 1H NMR (400 MHz,
DMSO-d6) δ/ppm: 1.88–2.15 (m, 4H, H5, H8), 2.76–2.81 (m, 1H H4), 3.50–3.59 (m, 4H, H6, H7), 4.32 (m,
2H, H2), 4.61 (s, 2H, Ar–CH2), 7.32–7.45 (m, 4H, H11, H13, H14, H15), 11.14 (s, 1H C=N–OH), 13C NMR
(101 MHz, DMSO-d6) δ/ppm: 21.40 (CH3), 23.49 (C5,C8), 27.46 (C4), 54.53 (C6, C7), 57.43 (C2), 66.74
(C9), 127.70 (C10), 129.42, 130.64, 131.40, 133.95 (C11-C15), 138.85 (C12), 151.44 (C3). CHN analysis/%:
Anal. calcd. for C15H21BrN2O: C 55.39, H 6.51, Br 24.57, N 8.61, O 4.92. Found: C 55.43, H 6.50, N 8.59.
N-(para-bromobenzyl)-3-hydroxyiminoquinuclidinium bromide (9). Yield: 95%; mp: 234.9–235.7 ◦C; IR
(KBr)
∼
ν/cm−1: 3346–2840, 1656, 1630, 1588, 1460, 1376, 1072, 945, 842. 1H NMR (400 MHz, DMSO-d6)
δ/ppm: 1.89–2.14 (m, 4H, H5, H8), 2.76–2.81 (m, 1H H4), 3.49–3.65 (m, 4H, H6, H7), 4.31 (m, 2H, H2),
4.66 (s, 2H, Ar–CH2), 7.48–7.53 (m, 2H, H11, H15), 7.73–8.79 (m, 2H, H12, H14), 11.14 (s, 1H C=N–OH),
13C NMR (101 MHz, DMSO-d6) δ/ppm: 23.49 (C5, C8), 27.43 (C4), 54.55 (C6, C7), 57.29 (C2), 65.74 (C9),
124.67 (C10), 127.13 (C13), 132.54 (C11,C15), 135.60 (C12,C14), 151.34 (C3). CHN analysis/%: Anal.
calcd. for C14H18Br2N2O: C 43.10, H 4.65, Br 40.96, N 7.18, O 4.10. Found: C 43.99, H 4.64, N 7.20.
N-(meta-bromobenzyl)-3-hydroxyiminoquinuclidinium bromide (10). Yield: 89%; mp: 221.7–222.4 ◦C;
IR (KBr)
∼
ν/cm−1: 3481, 3360–2801, 1673, 1569, 1431, 1377, 1215, 1064, 943, 719, 711. 1H NMR (400 MHz,
DMSO-d6) δ/ppm: 1.89–2.15 (m, 4H, H5, H8), 2.78–2.81 (m, 1H H4), 3.50–3.63 (m, 4H, H6, H7), 4.34
(s, 2H, H2), 4.67 (s, 2H, Ar–CH2), 7.48–7.54 (m, 1H, H14), 7.56–7.59 (m, 1H, H15), 7.75–7.78 (m, 1H,
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H13), 7.80–7.82 (m, 1H, H11), 11.15 (s, 1H C=N–OH), 13C NMR (101 MHz, DMSO-d6) δ/ppm: 23.51
(C5,C8), 27.40 (C4), 54.72 (C6, C7), 57.44 (C2), 65.64 (C9), 122.57 (C10), 130.38 (C12), 131.64, 132.69,
133.68, 135.95, (C11-C15), 151.32 (C3). CHN analysis/%: Anal. calcd. for C14H18Br2N2O: C 43.10, H
4.65, Br 40.96, N 7.18, O 4.10. Found: C 43.21, H 4.65, N 7.16.
3.2. Antimicrobial Evaluation
The tested microorganisms were obtained from the culture collection at the American
Type Culture Collection (ATCC) (Rockville, MD, USA) and at the Microbiology laboratory,
Department of Biology, Faculty of Natural Science, University of Split, Croatia (FNSST). The assayed
collection included gram-positive bacteria Bacillus cereus (ATCC 11778), Enterococcus faecalis (ATCC
29212), and Staphylococcus aureus (ATCC 25923) and three gram-negative ampicillin-resistant
environmental bacterial strains Escherichia coli (FNSST 111), Klebsiella pneumoniae (FNSST 014),
and Pseudomonas aeruginosa (FNSST 982). All gram-negative strains were resistant to first- and
second-generation cephalosporins, penicillins, quinolones, tetracyclines, gentamicin, and trimethoprim
as determined previously [24]. Bacterial strains were cultured overnight at 37 ◦C in tryptic soy broth
(TSB) to achieve optical densities corresponding to 106 colony forming units (cfu/mL) for bacteria.
All strains were grown in lysogenic broth (LB) media while being shaken at 150 rpm for 12 h at 37
◦C. Part of the bacterial suspension (100 µL) was transferred to a vial containing 5 mL of LB media
and incubated for 2 h at 37 ◦C to get mid logarithmic phase growth of bacteria. Finally, the bacterial
suspension was diluted using a phosphate buffer saline (PBS, pH 7.2) to achieve 105 bacteria/mL.
3.2.1. Disc Diffusion Assay
In order to investigate the antimicrobial activities of the synthesized N-alkyl derivatives of
quinucline-3-oximes, a disc diffusion assay was employed according to the Clinical and Laboratory
Standards Institute (CLSI) guidelines [25]. Briefly, 100 µL of suspension containing 105 colony-forming
units (cfu/mL) of bacterial cells was spread on a Mueller Hinton agar (Becton Dickinson, Sparks, MD).
The stock solutions of quaternary salts were prepared by dissolving in sterile distilled water to a final
concentration of 10 mg/mL. The sterile filter discs (6 mm) were individually loaded with 25 µL of the
stock solution, equivalent to a final concentration of 250 µg/disc of synthesized compounds, and then
placed on the nutrient agar that had been previously inoculated with the target microbial strains.
The plates were incubated for 24 h at 37 ◦C for the bacterial strain. Antibacterial activity was assessed
by measuring the diameter of the inhibition zone in millimetres, including disc diameter for the test
isolates. Samples were assayed in triplicate for each condition, and the diameters of inhibition zones
were presented as mean values.
3.2.2. Minimum Inhibitory Concentration Assay
In addition, antimicrobial activities of the synthesized compounds were tested by a broth
microdilution assay in 96-well microtitre plates. The standard two-fold serial microdilution assay
described by the Clinical and Laboratory Standards Institute [24] was performed for the assessment of
the minimum inhibitory concentrations (MICs). Bacteria were grown overnight in Mueller–Hinton
broth (MHB) at 37 ◦C to the stationary phase. The microbial cultures were diluted in fresh MHB to
a final concentration of 105 cfu/mL for bacteria. The tested compounds dissolved in sterile distilled
water to the highest concentration of 10 mg/mL. The stock solution and reference drugs were then
serially two-fold diluted to obtain concentrations ranging from 0.06–1024 µg/mL in sterile plates
containing Mueller Hinton broth (MHB) for bacterial. Serial dilutions of the compounds were added
to the microtiter plates in a volume of 100 µL. Each well was additionally inoculated with 100 µL
of inoculums of the target microorganism and incubated at 37 ◦C for 18–24 h. The MIC value was
determined as the lowest concentration of the sample at which the tested microorganisms did not
demonstrate any visible growth after incubation. As an indicator of bacterial growth, 50 µL of
0.2 mg/mL p-iodonitrotetrazolium chloride (INT; Sigma-Aldrich Co. Ltd., Poole, UK) was added to
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the wells and incubated at 37 ◦C for 30 min. Following addition of INT and incubation, the MIC was
determined as the lowest sample concentration at which no pink color appeared. Cefotaxime and
gentamicin were used as positive controls.
3.3. MTT Assay
In order to investigate the effect of the compounds on normal human cells, two normal human
cell lines were used, HMEC-1, human dermal microvascular endothelium cell line, and HaCaT,
human keratinocyte cell line. Both cell lines were cultured in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal calf serum (FCS). Cells were cultivated on 37 ◦C in 5% CO2
humidified atmosphere.
For the cell viability screening assay, all compounds were used at concentrations 1 µM, 10 µM,
and 100 µM. Then, the viability assay was repeated with the compounds that showed antimicrobial
activity with a wider concentration range.
Cells were seeded at 104 cells/well left for 24 h to attach. The next day cells were treated, and all
compounds were used at concentrations of 1 µM, 10 µM, and 100 µM. For the compounds that showed
antimicrobial activity, a wider range of drug concentrations was used to calculate IC50.
In order to perform proper controls, the compounds were dived into two groups, water and DMSO
soluble. DMSO controls were used at the equivalent concentration present in compound dilutions.
Additional controls of the assay were performed with the same experimental scheme with H2O2 and
kanamycin as cytotoxic and known antibiotics with serial double dilutions starting from 400 µM and
1600 µg/mL, respectively (Figure 4). After 24 h, cell viability was determined by an MTT-based assay,
EZ4U, following the manufacturer’s recommendations (Biomedica, Vienna, Austria). The assay is
based on the reduction of the colorless dye in mitochondria of the living cell to the yellow, water-soluble
derivative. Briefly, cells were incubated with the MTT dye for an hour, and the absorbance was
measured on a plate reader at 450 nm with reference wavelength at 620 nm (Easy-Reader 400 FW;
SLT-Lab Instruments, GmbH, Grödig, Austria).
ROS
Cells were seeded at 104 cells/well left for 24 h to attach. The next day, cells were incubated with
2,7-dichlorodihydrofluorescein diacetate (DCFH-DA, Fluka, Honeywell Research Chemicals, Charlotte,
NC, USA) for 60 minutes. This nonfluorescent dye is deacetylized inside the cells and, after oxidation
by intracellular ROS, turns fluorescent. After removing the excess dye, cells were washed once and
were treated with the compounds in a range of concentrations. Additional controls of the assay were
performed with the same experimental scheme with H2O2 and kanamycin as representative of ROS
and known antibiotics with serial double dilutions starting from 400 µM and 1600 µg/mL, respectively
(Figure 5). Fluorescence intensity was measured after 1 h on spectrofluorimeter Varian Cary Eclipse
(λex = 500 nm, λem = 529 nm).
3.4. Antioxidant Measurements
To assess the effects of the compounds on the cellular antioxidative system, cells were seeded
at 0.5 × 106 cell/well and treated with compounds qox, 6, 9, and 10 at concentrations of 5 µM and
200 µM. As controls, cells were grown only in DMEM with 10% FCS and with the addition of
DMSO in equivalent concentrations to ones present in compound dilutions. Cells were harvested by
trypsinization 24 h after treatment, and dry pellets were stored at −80 ◦C until analysis. For analysis,
cells were lysed in PBS by four freeze/thaw cycles, and the debris was removed by centrifugation
at 14,000 g for 15 min. The catalase activity was measured by a modified method of Goth [26,27].
For catalase activity assay, 40 µL of supernatant was mixed with 65-mM H2O2 for the start of the
reaction. The reaction was stopped after 5 minutes by the addition of 100 µL of 200-mM ammonium
molybdate and colour development was measured spectrophotometrically in a plate reader at 405 nm
(Shimadzu UV-1601, Kyoto, Japan). One unit of catalase activity is defined as the amount of enzyme
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needed for the degradation of 1 µmol of H2O2/min at 25 ◦C. Catalase activity was expressed as units
per milligram of proteins in cell lysate (U mg−1).
The intracellular GSH content was measured by modification of the protocol described by
Tietze [28]. Briefly, 150 µL of samples diluted to 0.03 mg/mL protein was used for the the reaction,
which started by the addition of freshly prepared reaction mix: 1.8-mM 5,5-dithio-bis-2-nitrobenzoic
acid, 0.4 Units of GSH reductase, and 0.6-mM NADPH in phosphate buffer (100-mM NaH2PO4, 5-mM
EDTA pH 7.4). The formation of 2-nitro-5-thiobenzoic acid was monitored spectrophotometrically in a
plate reader at 405 nm (Shimadzu UV-1601, Japan). GSH concentration in cell lysates was expressed as
µM of GSH per milligram of total protein (nmol mg−1).
3.5. Statistical Analysis
All experiments were performed in biological and technical triplicates. The inhibitory
concentrations of 50% (IC50) were calculated using nonlinear regression curve fitting log(inhibitor)
vs. response and variable slope with a least squares (ordinary) fit, using GraphPadPrism Version 5
software (grAphPad Corporation, San Diego, CA, USA). Statistical analyses were performed using
two-way analysis of variance (ANOVA) with Bonferroni post hoc test and Student’s t-test using the
same software. Values of P < 0.05 were considered significant.
3.6. Computational Methods
Conformational analysis for all compounds was performed by using the tensor decomposition of
ab initio molecular dynamics trajectories using the previously published procedure [23]. Ab initio
molecular dynamics were performed using on-the-fly calculations of forces in each point of the
simulation and integration with the velocity Verlet algorithm. The forces were calculated using the
PM7 method [29] implemented in MOPAC2016 (Stewart Computational Chemistry, Colorado Springs,
CO, USA) [30]. All molecular dynamics simulations were performed using our own program qcc (T.
Hrenar, Zagreb, Croatia) [31,32]. To ensure that most of the phase space relevant to the conformational
space of the investigated compounds was adequately sampled, the initial temperature for the Maxwell
distribution of velocities was set at 673.15 K, and this temperature was kept constant throughout
simulations using a velocity scaling algorithm. The step size was 0.5 fs, and the total length of
simulation was 2.5 ns (a total of 5,000,000 steps).
Tensor Decomposition: Molecular dynamics trajectories were decomposed using the principal
component analysis implemented in program moonee (T. Hrenar, Zagreb, Croatia) [33–35].
Local maxima from corresponding probability distribution were determined and used as an initial
guess for geometry optimization of structures at the B3LYP-D3/6-311++G(d,p) level of the theory.
After geometry optimizations, clustering of obtained geometries produced the full conformational
space of each investigated compound. All quantum-chemical calculations were performed using the
Gaussian 16 program (Gaussian, Inc., Wallingford, CT, USA) [36]. Figures were plotted using graphing
utility within free and open-source program Gnuplot 5.0. [37].
Potential energy surfaces: Potential energy surfaces for conformers of the lowest energy were
calculated by systematic variation of torsional angles for the chemical groups attached to the nitrogen
atom. For each point, an energy calculation for the structure was performed using the Gaussian
16 program package [36]. Energy values were arranged in data matrix or 2nd-order data tensors
and combined for all investigated compounds, making a 3rd-order data tensor. This tensor was
decomposed by using Tucker3 tensor decomposition method [38].
4. Conclusions
The antimicrobial profiles of presented novel N-alkyl derivatives of quinuclinium oximes 1–10
were determined. Compounds 5 and 10 (MIC values 0.25 µg/mL) demonstrated a very high potential
in combating multidrug-resistant gram-negative bacterial strains, especially the emerging pathogen
Pseudomonas aeruginosa. Both compounds showed broad spectrum antimicrobial activity against
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gram-positive and gram-negative bacteria. Compounds have no inhibitory effects on normal human
cells growth and are suitable for further development. Continued studies on these molecules, including
combinatorial therapies with conventional antibiotics and animal modeling, will enable the elucidation
of the mechanisms by which these derivatives provide a potent antimicrobial effect. Regression model
between the biological activity and potential energy surfaces was established using the tensor reduction
techniques. The high R2 value of the established model confirms the capabilities of the model to
describe the biological activity of investigated compounds in relation to their potential energy surfaces.
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